Oragenics Inc., a clinical-stage biotechnology company developing intranasal therapeutics for neurological disorders, announced its participation at the SCOPE Summit 2026, the 17th annual Summit for Clinical Ops Executives organized by the Cambridge Healthtech Institute. The event will be held from February 2 to February 5, 2026, in Orlando, Florida. The company plans to engage with leaders across biopharma, clinical research, regulatory affairs, and clinical technology as it advances its proprietary intranasal delivery platform.
The participation comes as Oragenics prepares for a Phase 2a clinical trial in Australia of ONP-002, its therapeutic candidate for concussion and mild traumatic brain injury. These areas represent significant unmet medical needs with no FDA-approved treatments currently available. The company's work on ONP-002 positions it as a potential first-in-class treatment for these conditions, which affect millions of people worldwide annually.
Oragenics' intranasal delivery platform has broader applications beyond concussion treatment. The technology shows potential for addressing multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. This platform approach could revolutionize how neurological disorders are treated by enabling direct delivery of therapeutics to the brain through the nasal pathway.
The company's clinical development strategy involves commencing trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. This international approach to clinical development reflects the global nature of neurological disorders and the need for innovative treatments across healthcare systems. More information about the company's development programs can be found at https://oragenics.com.
The SCOPE Summit participation provides Oragenics with an opportunity to share insights with industry leaders about clinical operations and regulatory strategies. As the company advances toward its Phase 2a trial, engagement with the clinical research community becomes increasingly important for successful trial design and execution. The full details of the company's announcement are available in the press release at https://ibn.fm/pSKAx.
For investors and stakeholders following Oragenics' progress, the latest news and updates relating to the company are available through its newsroom at https://ibn.fm/OGEN. The company's participation in industry events like SCOPE Summit 2026 demonstrates its commitment to advancing neurological care through innovative therapeutic approaches. As Oragenics moves forward with its clinical development programs, the biotechnology community will be watching closely for results that could potentially transform treatment options for patients with neurological disorders.
